Cargando…

Role of integrin expression in the prediction of response to vedolizumab: A prospective real‐life multicentre cohort study

Detalles Bibliográficos
Autores principales:	De Galan, Cara, Gonzales, Gerard Bryan, Van Welden, Sophie, Tavernier, Simon Jan, Lobaton, Triana, Van Moerkercke, Wouter, Strubbe, Beatrijs, Peeters, Harald, Macken, Elisabeth, De Vos, Martine, Laukens, Debby, Hindryckx, Pieter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Letter to Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8982506/ https://www.ncbi.nlm.nih.gov/pubmed/35384344 http://dx.doi.org/10.1002/ctm2.769

Ejemplares similares

Long-Term Environmental Hypoxia Exposure and Haematopoietic Prolyl Hydroxylase-1 Deletion Do Not Impact Experimental Crohn’s Like Ileitis
por: De Galan, Cara, et al.
Publicado: (2021)

Differential expression of prolyl hydroxylase 1 in patients with ulcerative colitis versus patients with Crohn’s disease/infectious colitis and healthy controls
por: Van Welden, Sophie, et al.
Publicado: (2013)

Optimal Management of Acute Severe Ulcerative Colitis (ASUC): Challenges and Solutions
por: Holvoet, Tom, et al.
Publicado: (2021)

Assessment of faecal microbial transfer in irritable bowel syndrome with severe bloating
por: Holvoet, Tom, et al.
Publicado: (2017)

Evidence for a Potential Role of Metallothioneins in Inflammatory Bowel Diseases
por: Waeytens, Anouk, et al.
Publicado: (2009)

Prevalence of Fatigue and Unrecognized Depression in Patients with Inflammatory Bowel Disease in Remission under Immunosuppressants and Biologicals
por: Truyens, Marie, et al.
Publicado: (2021)

Involvement of Endoplasmic Reticulum Stress in Inflammatory Bowel Disease: A Different Implication for Colonic and Ileal Disease?
por: Bogaert, Sara, et al.
Publicado: (2011)

Vedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel disease
por: Singh, Harmanjit, et al.
Publicado: (2016)

α4β7 Integrin Antagonist Vedolizumab for the Treatment of Refractory Ileitis
por: Filip, Rafał, et al.
Publicado: (2019)

Heterogeneity of the gut microbiome in mice: guidelines for optimizing experimental design
por: Laukens, Debby, et al.
Publicado: (2015)

Evidence for Significant Overlap between Common Risk Variants for Crohn's Disease and Ankylosing Spondylitis
por: Laukens, Debby, et al.
Publicado: (2010)

Differential mucosal expression of Th17-related genes between the inflamed colon and ileum of patients with inflammatory bowel disease
por: Bogaert, Sara, et al.
Publicado: (2010)

Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases
por: Rath, Timo, et al.
Publicado: (2018)

Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles
por: Fuchs, Friederike, et al.
Publicado: (2017)

Measuring Serum Vedolizumab and Vedolizumab Antibodies: Comparison of Commercial Assays with the Vedolizumab Clinical Development Assay
por: Vande Casteele, Niels, et al.
Publicado: (2023)

Translational research into the effects of cigarette smoke on inflammatory mediators and epithelial TRPV1 in Crohn’s disease
por: Allais, Liesbeth, et al.
Publicado: (2020)

Possible Efficacy of Vedolizumab, an Anti-α4β7 Integrin Antibody, in Palmoplantar Pustulosis
por: Terui, Hitoshi, et al.
Publicado: (2023)

Vedolizumab-Associated Hypereosinophilia and Hepatoxicity
por: De Marco, Davide, et al.
Publicado: (2022)

Butyrate-producing bacteria supplemented in vitro to Crohn’s disease patient microbiota increased butyrate production and enhanced intestinal epithelial barrier integrity
por: Geirnaert, Annelies, et al.
Publicado: (2017)

Lymphoplasmacellular mucositis ameliorated by α4β7 integrin inhibitor vedolizumab in a patient with ulcerative colitis
por: Shalabi, Doaa, et al.
Publicado: (2019)

Circulating exosomes express α(4)β(7) integrin and compete with CD4+ T cells for the binding to Vedolizumab
por: Domenis, Rossana, et al.
Publicado: (2020)

Vedolizumab blocks α4β7 integrin-mediated T cell adhesion to MAdCAM-1 in microscopic colitis
por: Besendorf, Laura, et al.
Publicado: (2022)

Vedolizumab for Inflammatory Bowel Disease: Two‐Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study: ICC Registry – Vedolizumab
por: Biemans, Vince B.C., et al.
Publicado: (2019)

Planned Retirement Timing in Europe: Are Europeans Adapting to the Policy of Extending Working Lives
por: Hess, Moritz, et al.
Publicado: (2021)

The Occurrence of Thrombosis in Inflammatory Bowel Disease Is Reflected in the Clot Lysis Profile
por: Bollen, Lize, et al.
Publicado: (2015)

Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn’s Disease: A Multi-Center Retrospective Cohort Study
por: Albshesh, Ahmad, et al.
Publicado: (2023)

The quorum sensing peptide EntF* promotes colorectal cancer metastasis in mice: a new factor in the host-microbiome interaction
por: Wynendaele, Evelien, et al.
Publicado: (2022)

Vedolizumab in the treatment of Crohn’s disease of the pouch
por: Khan, Freeha, et al.
Publicado: (2018)

Vedolizumab for chronic antibiotic-refractory pouchitis
por: Singh, Amandeep, et al.
Publicado: (2019)

The Early Experience With Vedolizumab in the United States
por: Kochar, Bharati, et al.
Publicado: (2019)

Combination of vedolizumab and immunomodulators in ulcerative colitis
por: Pinton, P
Publicado: (2021)

α4β7 integrin-dependent adhesion of T cells to MAdCAM-1 is blocked by vedolizumab in patients with chronic refractory pouchitis
por: Melde, Michaela, et al.
Publicado: (2021)

Chronic Cholestatic Liver Injury Attributable to Vedolizumab
por: Stine, Jonathan G., et al.
Publicado: (2016)

A Case of Evan's Syndrome Induced by Vedolizumab
por: Jen, Henry, et al.
Publicado: (2019)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Predicting Response to Vedolizumab in Inflammatory Bowel Disease
por: Meserve, Joseph, et al.
Publicado: (2020)

Vedolizumab Therapy in Refractory Enteropathy Associated With CVID
por: Johnson, Dane, et al.
Publicado: (2021)

Acute Chest Pain as an Infusion Reaction to Vedolizumab
por: Levartovsky, Asaf, et al.
Publicado: (2022)

Vedolizumab for induction and maintenance of remission in Crohn's disease
por: Hui, Samuel, et al.
Publicado: (2023)

Optimizing post-operative Crohn’s disease treatment
por: Domènech, Eugeni, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_dvatau6m8mdga0gjjkgbosrjti